AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Seres Therapeutics to Present at Three Upcoming March Conferences

March 5, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 5, 2019--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present at each of the following upcoming healthcare conferences:

  • Chardan’s Inaugural Microbiome Summit: a corporate overview will be presented on Thursday, March 7 th at 8:10 a.m. ET in New York, NY.
  • Cowen and Company 39 th Annual Health Care Conference: a corporate overview will be presented on Monday, March 11 th at 11:20 a.m. ET in Boston, MA.
  • Oppenheimer 29 th Annual Healthcare Conference: a corporate overview will be presented on Tuesday, March 19 th at 11:30 a.m. ET in New York, NY.

A live audio webcast of each presentation will be available under the “Investors and Media” section of Seres’ website. A replay will become available approximately one hour after each event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres’ most advanced program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for recurrent C. difficile infection. SER-287 is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is developing SER-401 in a Phase 1b study in metastatic melanoma to augment the efficacy of anti-PD-1 immunotherapy. For more information, please visit www.serestherapeutics.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190305005942/en/

CONTACT: IR or PR Contact:

Carlo Tanzi, Ph.D., Seres Therapeutics, 617-203-3467

Vice President, Investor Relations and Corporate Communications

ctanzi@serestherapeutics.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Seres Therapeutics, Inc.

Copyright Business Wire 2019.

PUB: 03/05/2019 04:00 PM/DISC: 03/05/2019 04:01 PM

http://www.businesswire.com/news/home/20190305005942/en